Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome

Christian E Sandrock, Andrew Norris

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In chronic persistent asthma and severe acute exacerbations of bronchial asthma, infectious agents are the predominant triggers that drive disease and airway pathobiology. In acute exacerbations of bronchial asthma (AEBA) including near fatal and fatal asthma, viral agents, particularly human rhinovirus-C, respiratory syncytial virus and influenza A appear to be the more prevalent and recurring threats. Both viral, and to a lesser extent bacterial agents, can play a role, and co-infection may also be present and worsen prognosis in hospitalized patients, placing a portion at risk for critical asthma syndrome. During severe acute exacerbations, infectious agents must be treated empirically, but the initial treatment regimens can vary and viral coverage may also vary based on seasonality and patient age. Early treatment with ceftriaxone and azithromycin, along with oseltamivir in winter months, should be initiated with all cases of severe exacerbations where infection is suspected, and definitely in critical asthma syndrome until infection is excluded by appropriate diagnostic testing. In this manuscript we will outline the impact of the major viral agents on severe asthma including the data from the 2009 H1N1 influenza pandemic. The role of bacterial infections in acute exacerbations of asthma will also be reviewed as well as the benefit of empiric antibiotics and the role of macrolides in both acute and chronic asthma.

Original languageEnglish (US)
Pages (from-to)104-113
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Volume48
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Asthma
Infection
Human Influenza
Oseltamivir
Rhinovirus
Azithromycin
Respiratory Syncytial Viruses
Ceftriaxone
Macrolides
Pandemics
Coinfection
Bacterial Infections
Anti-Bacterial Agents
Therapeutics

Keywords

  • Acute Exacerbation of Bronchial Asthma (AEBA)
  • Community acquired pneumonia
  • Critical asthma syndrome
  • Viral pneumonitis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome. / Sandrock, Christian E; Norris, Andrew.

In: Clinical Reviews in Allergy and Immunology, Vol. 48, No. 1, 2014, p. 104-113.

Research output: Contribution to journalArticle

@article{f9fd0282ee2744dbb4c5b8fcb8196b2a,
title = "Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome",
abstract = "In chronic persistent asthma and severe acute exacerbations of bronchial asthma, infectious agents are the predominant triggers that drive disease and airway pathobiology. In acute exacerbations of bronchial asthma (AEBA) including near fatal and fatal asthma, viral agents, particularly human rhinovirus-C, respiratory syncytial virus and influenza A appear to be the more prevalent and recurring threats. Both viral, and to a lesser extent bacterial agents, can play a role, and co-infection may also be present and worsen prognosis in hospitalized patients, placing a portion at risk for critical asthma syndrome. During severe acute exacerbations, infectious agents must be treated empirically, but the initial treatment regimens can vary and viral coverage may also vary based on seasonality and patient age. Early treatment with ceftriaxone and azithromycin, along with oseltamivir in winter months, should be initiated with all cases of severe exacerbations where infection is suspected, and definitely in critical asthma syndrome until infection is excluded by appropriate diagnostic testing. In this manuscript we will outline the impact of the major viral agents on severe asthma including the data from the 2009 H1N1 influenza pandemic. The role of bacterial infections in acute exacerbations of asthma will also be reviewed as well as the benefit of empiric antibiotics and the role of macrolides in both acute and chronic asthma.",
keywords = "Acute Exacerbation of Bronchial Asthma (AEBA), Community acquired pneumonia, Critical asthma syndrome, Viral pneumonitis",
author = "Sandrock, {Christian E} and Andrew Norris",
year = "2014",
doi = "10.1007/s12016-014-8435-x",
language = "English (US)",
volume = "48",
pages = "104--113",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome

AU - Sandrock, Christian E

AU - Norris, Andrew

PY - 2014

Y1 - 2014

N2 - In chronic persistent asthma and severe acute exacerbations of bronchial asthma, infectious agents are the predominant triggers that drive disease and airway pathobiology. In acute exacerbations of bronchial asthma (AEBA) including near fatal and fatal asthma, viral agents, particularly human rhinovirus-C, respiratory syncytial virus and influenza A appear to be the more prevalent and recurring threats. Both viral, and to a lesser extent bacterial agents, can play a role, and co-infection may also be present and worsen prognosis in hospitalized patients, placing a portion at risk for critical asthma syndrome. During severe acute exacerbations, infectious agents must be treated empirically, but the initial treatment regimens can vary and viral coverage may also vary based on seasonality and patient age. Early treatment with ceftriaxone and azithromycin, along with oseltamivir in winter months, should be initiated with all cases of severe exacerbations where infection is suspected, and definitely in critical asthma syndrome until infection is excluded by appropriate diagnostic testing. In this manuscript we will outline the impact of the major viral agents on severe asthma including the data from the 2009 H1N1 influenza pandemic. The role of bacterial infections in acute exacerbations of asthma will also be reviewed as well as the benefit of empiric antibiotics and the role of macrolides in both acute and chronic asthma.

AB - In chronic persistent asthma and severe acute exacerbations of bronchial asthma, infectious agents are the predominant triggers that drive disease and airway pathobiology. In acute exacerbations of bronchial asthma (AEBA) including near fatal and fatal asthma, viral agents, particularly human rhinovirus-C, respiratory syncytial virus and influenza A appear to be the more prevalent and recurring threats. Both viral, and to a lesser extent bacterial agents, can play a role, and co-infection may also be present and worsen prognosis in hospitalized patients, placing a portion at risk for critical asthma syndrome. During severe acute exacerbations, infectious agents must be treated empirically, but the initial treatment regimens can vary and viral coverage may also vary based on seasonality and patient age. Early treatment with ceftriaxone and azithromycin, along with oseltamivir in winter months, should be initiated with all cases of severe exacerbations where infection is suspected, and definitely in critical asthma syndrome until infection is excluded by appropriate diagnostic testing. In this manuscript we will outline the impact of the major viral agents on severe asthma including the data from the 2009 H1N1 influenza pandemic. The role of bacterial infections in acute exacerbations of asthma will also be reviewed as well as the benefit of empiric antibiotics and the role of macrolides in both acute and chronic asthma.

KW - Acute Exacerbation of Bronchial Asthma (AEBA)

KW - Community acquired pneumonia

KW - Critical asthma syndrome

KW - Viral pneumonitis

UR - http://www.scopus.com/inward/record.url?scp=84939888159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939888159&partnerID=8YFLogxK

U2 - 10.1007/s12016-014-8435-x

DO - 10.1007/s12016-014-8435-x

M3 - Article

C2 - 24984968

AN - SCOPUS:84939888159

VL - 48

SP - 104

EP - 113

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 1

ER -